Stéphane Marie. Oudard
Inserm · 1,324 works · 67,864 citations · h-index 103
Top works
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma